THE TRANSITORY PTH INCREASE FOLLOWING DENOSUMAB ADMINISTRATION IS ASSOCIATED WITH REDUCED INTRACORTICAL POROSITY: A DISTINCTIVE CHARACTERISTIC OF DENOSUMAB THERAPY
Ego Seeman(The University of Melbourne), John P. Bilezikian(Columbia University), José Zanchetta(Universidad del Salvador), Matthew Austin(Amgen (United States)), Roland Chapurlat(Université Claude Bernard Lyon 1), Steven K. Boyd(Alberta Bone and Joint Health Institute), David A. Hanley(The University of Sydney), Andreas Grauer(Omeros Corporation (United States)), Roger Zebaze(Austin Health), Cesar Libanati(Amgen (United States))
Osteoporosis International
January 1, 2012
Cited by 1
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions
|Endocrine Reviews|2018|1.1k